Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
Oct 2021
Historique:
revised: 19 05 2021
received: 12 04 2021
accepted: 01 06 2021
pubmed: 4 6 2021
medline: 20 8 2021
entrez: 3 6 2021
Statut: ppublish

Résumé

Geographical variation in severe acute respiratory syndrome coronavirus 2 (SARS--CoV--2) spread requires seroprevalence studies based on local tests, but robust validation is needed. We summarize an evaluation of antibody tests used in a serological study of SARS--CoV--2 in Saint Petersburg, Russia. We validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS--CoV--2 immunoglobulin G (IgG), enzyme- linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA SARS--CoV--2--IgG--EIA--BEST. Clinical sensitivity was estimated with the SARS--CoV--2 polymerase chain reaction (PCR) test as the gold standard using manufacturer recommended cutoff. Specificity was estimated using pre-pandemic sera samples. The median time between positive PCR test results and antibody tests was 21 weeks. Measures of concordance were calculated against the microneutralization test (MNA).Sensitivity was equal to 91.1% (95% confidence intervbal [CI]: 78.8-97.5), 90% (95% CI: 76.4-96.4), and 63.1% (95% CI [50.2-74.7]) for ELISA Coronapass, ELISA Vector-Best, and CMIA Abbott, respectively. Specificity was equal to 100% for all the tests. Comparison of receiver operating characteristics has shown lower AUC for CMIA Abbott. The cut-off SC/O ratio of 0.28 for CMIA Abbott resulted in a sensitivity of 80% at the same level of specificity. Less than 33% of the participants with positive antibody test results had neutralizing antibodies in titers 1:80 and above. Antibody assays results and MNA correlated moderately. This study encourages the use of local antibody tests and sets the reference for seroprevalence correction. Available tests' sensitivity allows detecting antibodies within the majority of PCR- positive individuals. The Abbott assay sensitivity can be improved by incorporating a new cut-off. Manufacturers' test characteristics may introduce bias into the study results.

Identifiants

pubmed: 34081328
doi: 10.1002/jmv.27126
pmc: PMC8242745
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5846-5852

Subventions

Organisme : Polymetal International plc

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Clin Microbiol Infect. 2021 Jun;27(6):933-935
pubmed: 33450388
Clin Microbiol Infect. 2020 Sep;26(9):1256.e9-1256.e11
pubmed: 32531475
Eur J Epidemiol. 2020 Apr;35(4):331-333
pubmed: 32318914
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
J Clin Virol. 2021 May;138:104797
pubmed: 33770657
J Clin Virol. 2020 Aug;129:104540
pubmed: 32652475
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
J Med Virol. 2021 Oct;93(10):5846-5852
pubmed: 34081328
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115297
pubmed: 33388574
Natl Sci Rev. 2021 Jan 11;8(4):nwab006
pubmed: 34676097
Epidemiol Infect. 2010 Nov;138(11):1674-8
pubmed: 20196903
BMC Infect Dis. 2021 Feb 18;21(1):187
pubmed: 33602152
Clin Microbiol Infect. 2021 Mar;27(3):469.e9-469.e15
pubmed: 33068757
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33106364
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
J Clin Epidemiol. 1993 May;46(5):423-9
pubmed: 8501467
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
J Clin Microbiol. 2021 Apr 20;59(5):
pubmed: 33574119
JAMA Intern Med. 2021 May 1;181(5):672-679
pubmed: 33625463
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMC Med Res Methodol. 2020 Mar 14;20(1):65
pubmed: 32171240
J Clin Virol. 2020 Nov;132:104645
pubmed: 32961429

Auteurs

Anton Barchuk (A)

Institute for Interdisciplinary Health Research (I2HR), European University at St. Petersburg, St. Petersburg, Russia.
NN Petrov National Research Medical Center of Oncology, St. Petersburg, Russia.

Daniil Shirokov (D)

Clinic "Scandinavia" (LLC Ava-Peter), St. Petersburg, Russia.
Publication Activity Development Center, ITMO University, St. Petersburg, Russia.

Mariia Sergeeva (M)

Department of Vaccinology, Smorodintsev Research Institute of Influenza, St. Petersburg, Russia.

Rustam Tursun Zade (R)

Institute for Interdisciplinary Health Research (I2HR), European University at St. Petersburg, St. Petersburg, Russia.

Olga Dudkina (O)

Institute for Interdisciplinary Health Research (I2HR), European University at St. Petersburg, St. Petersburg, Russia.

Varvara Tychkova (V)

Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia.

Lubov Barabanova (L)

Clinic "Scandinavia" (LLC Ava-Peter), St. Petersburg, Russia.

Dmitriy Skougarevskiy (D)

Institute for the Rule of Law, European University at Saint Petersburg, Saint Petersburg, Russia.

Daria Danilenko (D)

Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH